ARS Pharmaceuticals (SPRY) Receivables (2023 - 2026)
ARS Pharmaceuticals (SPRY) posted Receivables of $28.7 million for Q1 2026, up 13.08% sequentially from $25.3 million in Q4 2025, and up 179.19% YoY from $10.3 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Receivables (2023 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Receivables for 4 years, with the latest figure at $28.7 million in Q1 2026.
- Quarterly Receivables rose 179.19% year-over-year to $28.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.7 million (up 179.19% YoY) and the FY2025 annual result came in at $25.3 million, up 169.45% from the prior year.
- Receivables rose to $28.7 million in Q1 2026 per SPRY's latest filing, from $25.3 million in the prior quarter.
- Over five years, Receivables peaked at $40.7 million in Q3 2025 and troughed at $652000.0 in Q4 2023.
- A 4-year average of $17.9 million and a median of $17.8 million in 2025 frame the typical range for Receivables.
- The widest YoY moves for Receivables: up 4394.48% in 2025, down 169.45% in 2025.
- Over 4 years, Receivables stood at $652000.0 in 2023, then surged by 1342.79% to $9.4 million in 2024, then soared by 169.45% to $25.3 million in 2025, then advanced by 13.08% to $28.7 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $28.7 million, $25.3 million, and $40.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 46.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.84 Mn |
| Mar 31, 2026 | 28.66 Mn |
| Dec 31, 2025 | 25.35 Mn |
| Sep 30, 2025 | 40.72 Mn |
| Jun 30, 2025 | 27.15 Mn |
| Mar 31, 2025 | 10.27 Mn |
| Dec 31, 2024 | 9.41 Mn |
| Sep 30, 2024 | 906,000.00 |
| Dec 31, 2023 | 652,000.00 |